Cargando…
What can we learn from molecular dynamics simulations for GPCR drug design?
Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334948/ https://www.ncbi.nlm.nih.gov/pubmed/25709761 http://dx.doi.org/10.1016/j.csbj.2014.12.002 |
_version_ | 1782358257931649024 |
---|---|
author | Tautermann, Christofer S. Seeliger, Daniel Kriegl, Jan M. |
author_facet | Tautermann, Christofer S. Seeliger, Daniel Kriegl, Jan M. |
author_sort | Tautermann, Christofer S. |
collection | PubMed |
description | Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R). |
format | Online Article Text |
id | pubmed-4334948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-43349482015-02-23 What can we learn from molecular dynamics simulations for GPCR drug design? Tautermann, Christofer S. Seeliger, Daniel Kriegl, Jan M. Comput Struct Biotechnol J Article Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R). Research Network of Computational and Structural Biotechnology 2014-12-10 /pmc/articles/PMC4334948/ /pubmed/25709761 http://dx.doi.org/10.1016/j.csbj.2014.12.002 Text en © 2014 The Authors. Tautermann et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Tautermann, Christofer S. Seeliger, Daniel Kriegl, Jan M. What can we learn from molecular dynamics simulations for GPCR drug design? |
title | What can we learn from molecular dynamics simulations for GPCR drug design? |
title_full | What can we learn from molecular dynamics simulations for GPCR drug design? |
title_fullStr | What can we learn from molecular dynamics simulations for GPCR drug design? |
title_full_unstemmed | What can we learn from molecular dynamics simulations for GPCR drug design? |
title_short | What can we learn from molecular dynamics simulations for GPCR drug design? |
title_sort | what can we learn from molecular dynamics simulations for gpcr drug design? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334948/ https://www.ncbi.nlm.nih.gov/pubmed/25709761 http://dx.doi.org/10.1016/j.csbj.2014.12.002 |
work_keys_str_mv | AT tautermannchristofers whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign AT seeligerdaniel whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign AT kriegljanm whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign |